Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 4Breast 4Gastrointestinal 3Tumor-Agnostic 2Other solid neoplasm 2Plasma cell 1NET 1Endocrine 1

Conditions

Colorectal Neoplasms 2Pancreatic Neoplasms 1

Interventions

Fluorouracil 616Oxaliplatin 579Gemcitabine 492Capecitabine 445Leucovorin 427Irinotecan 390Bevacizumab 330Cisplatin 320Radiotherapy 245Cetuximab 215Sorafenib 167pembrolizumab 152Docetaxel 150Paclitaxel 140Nivolumab 128Albumin-Bound Paclitaxel 108130-nm albumin-bound paclitaxel 108Folfox protocol 101Panitumumab 95Erlotinib Hydrochloride 95Surgical Procedures, Operative 86regorafenib 84S 1 (combination) 81Drug Therapy 80Radiation 69Carboplatin 65Neoadjuvant Therapy 64Colonoscopy 64Radiosurgery 63Surveys and Questionnaires 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × dalotuzumab × Gastrointestinal × Clear all
NCT00769483 2020-09-03

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
81 enrolled 19 charts
Gastrointestinal

Pancreatic Neoplasms

NCT00925015 2018-08-15

Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)

Merck Sharp & Dohme LLC

Phase 1 Completed
20 enrolled 30 charts
Gastrointestinal

Colorectal Neoplasms

NCT00614393 2018-08-08

Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)

Merck Sharp & Dohme LLC

Phase 2 Completed
558 enrolled 17 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡